- Catalyst fund and company seek to sell shares for C$11 to C$13
- Mississauga-based Therapure focuses on biopharmaceuticals
Therapure Biopharma Inc., a biopharmaceutical firm held by Catalyst Capital Group Inc., is seeking to raise about C$130 million ($92.2 million) by selling shares in its initial public offering, according to an amended filing with Canadian regulators.
Therapure and one of Catalyst Capital’s funds aim to sell shares for C$11 to C$13 apiece in the initial offering, according to a Wednesday filing with regulators. GMP Capital Inc., Canadian Imperial Bank of Commerce and National Bank of Canada are arranging the Therapure sale.
Therapure is focused on making pharmaceutical products made out of living organisms and on developing, manufacturing and selling its own blood and plasma-related products, the Mississauga, Ontario-based company said in the filing. Therapure’s development has primarily been supported by a fund managed by Catalyst, a Toronto-based firm founded by Newton Glassman.